Clarivate Identifies Thirteen Potential Blockbuster Drugs an

Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies
LONDON, Jan....

Related Keywords

London , City Of , United Kingdom , Derwent , Derbyshire , China , Canada , Chinese , Eli Lilly , Verona Pharma , Mirikizumab Omvoh , Daiichi Sankyo , Mike Ward , Catherine Daniel , Pfizer Inc , Astellas Pharma Inc , Vertex Pharmaceuticals Inc , Clarivate Plc , Bioverativ Therapeutics Inc , Gilead Sciences Inc , Life Sciences , Life Sciences Healthcare , Life Sciences Healthcare On Linkedin , Astrazeneca , European Commission , Regeneron Pharmaceuticals Inc , Mainland China , Global Head , Thought Leadership , Regeneron Pharmaceuticals , Calliditas Therapeutics , Everest Medicines , Therapeutics Inc , Swedish Orphan Biovitrum , Bluebird Bio , Johnson Innovative , Astellas Pharma , Clarivate Drugs , Cortellis Competitive Intelligence , Disease Landscape , Drug Timeline , Success Rates , Cortellis Clinical Trials Intelligence , Cortellis Generics Intelligence , Cortellis Deals Intelligence , Clarivate Real World Data , Derwent Innovation , Canada Newswire , Markets ,